CESI-MS System for Therapeutic Biologics

The CESI 8000 System for Biologics Characterization from AB Sciex, an innovative, high-performance separation-electrospray ionization system for mass spectrometry (MS), marks a novel combination of capillary electrophoresis (CE) and electrospray ionization (ESI) technologies to create an integrated workflow solution. This new front-end CESI technology from the company's SCIEX Separations business can be integrated with the well-established AB Sciex TripleTOF 5600 mass spectrometry system into a seamless solution, for example, to give biopharmaceutical scientists the ability to advance therapeutics discovery, research and development through the life cycle of the product.

With a single approach that increases efficiency and productivity, the CESI 8000 system provides orthogonal and/or superior results compared to dual-method liquid chromatography / mass spectrometry-based approaches.  From a single digest and run, users of CESI-MS gain the following: (a) Identity and Purity information with 100 percent coverage in a peptide map; (b) Heterogeneity information with ultrasensitive glycopeptide quantitation; and (c) Stability information identifying, deamidation, cyclization and oxidation ‒ all highly important to biopharmaceutical scientists.

The technical benefit of the CESI innovation delivered to biopharmaceutical laboratories is an improvement in biophysicochemical characterization to guide the development of biologics-based therapeutics.  Specifically, CESI-MS serves to improve ionization efficiency and reduce ion suppression.  This advancement offers a robust solution without requiring specialized expertise in CE or MS.

Switching between LC-MS and CESI-MS has also been made simple, which will help facilitate adoption of CESI-MS technology.  The data that is generated on the CESI-based workflow is complementary to data from LC-MS/MS solutions.

AB Sciex, www.sciex.com/cesi